dasatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 785 302962-49-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasatinib
  • sprycel
  • spyrcel
  • BMS-354825
  • dasatinib hydrate
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
  • Molecular weight: 488.01
  • Formula: C22H26ClN7O2S
  • CLOGP: 2.71
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 106.51
  • ALOGS: -4.58
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.85 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.333 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 34.119 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 10.162 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 22.233 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 10.130 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 20.340 % Moderate 0.72
herg hERG pIC50 4.850 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 19.634 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 73.621 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 5.180 % Moderate 0.72
kinase-safety-class ABL1,ABL2,ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK19,CDK4,CDK5,CDK9,CSF1R,CSK,DDR1,DYRK1B,EGFR,EPHA2,EPHB1,EPHB3,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FYN,GAK,GRK2,INSR,IRAK1,ITK,JAK1,JAK2,KDR,KIT,LCK,LYN,MAP3K1,MAP3K10,MAP3K11,MAP3K21,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK11,MAPK14,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK1,NTRK2,PDGFRB,PDK2,PDK4,PIK3CD,PIK3CG,PRKCD,PRKDC,PTK6,RET,RIPK3,SIK2,SIK3,SRC,STK10,STK33,SYK,TEK,TGFBR1,TNIK,TTK,TYRO3,ULK1,ULK2,YES1 90
kinase-selectivity-class ABL2,ACVR1B,ACVR2B,ACVRL1,ALK,AXL,BLK,BMX,BRAF,BTK,CAMK2D,CDK9,CSF1R,CSK,DDR1,EGFR,EPHA2,EPHB3,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FYN,GAK,GRK2,JAK1,KDR,KIT,LCK,LYN,MAP3K21,MAP4K1,MAP4K3,MAPK11,MAPK14,MAPK7,MET,MTOR,NTRK1,PAK4,PDGFRB,PDK4,PIK3CD,PRKCD,RET,RIPK3,SIK2,SIK3,SRC,SYK,TGFBR1,TYRO3,YES1 55
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 31.477 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 55.590 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 56.494 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 5.910 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 33.574 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 12.960 % Moderate 0.72
rat-kpuu-brain Rat brain Kpuu 0.009 % High 1
rh-clint Rat hepatocyte intrinsic clearance 37.325 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 34.310 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 7.160 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 7.834 uM Moderate 0.72

Approvals:

DateAgencyCompanyOrphan
June 28, 2006 FDA BRISTOL MYERS SQUIBB
Nov. 20, 2006 EMA BRISTOL-MYERS SQUIBB PHARMA EEIG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 1811.52 19.04 801 25440 111190 90491016
Drug resistance 424.49 19.04 197 26044 30252 90571954
Pulmonary oedema 393.13 19.04 237 26004 61843 90540363
Cytogenetic analysis abnormal 380.59 19.04 82 26159 928 90601278
Hospitalisation 376.08 19.04 305 25936 127795 90474411
Adverse event 349.78 19.04 282 25959 117136 90485070
Philadelphia chromosome positive 333.49 19.04 65 26176 425 90601781
Chylothorax 308.27 19.04 60 26181 389 90601817
Acute lymphocytic leukaemia recurrent 295.18 19.04 81 26160 2640 90599566
Pericardial effusion 252.30 19.04 148 26093 36685 90565521
Malignant neoplasm progression 235.31 19.04 216 26025 106654 90495552
Blast crisis in myelogenous leukaemia 234.09 19.04 51 26190 610 90601596
Nausea 213.85 19.04 754 25487 1109562 89492644
Death 198.14 19.04 419 25822 456132 90146074
Fatigue 193.88 19.04 750 25491 1153273 89448933
Diarrhoea 184.95 19.04 643 25598 938547 89663659
Bone pain 180.41 19.04 147 26094 61836 90540370
Exposure via body fluid 170.82 19.04 39 26202 585 90601621
Emergency care examination 164.07 19.04 30 26211 131 90602075
Fluid retention 163.35 19.04 162 26079 87929 90514277
Headache 158.77 19.04 578 25663 862168 89740038
Prescribed underdose 148.49 19.04 143 26098 74876 90527330
Rash 132.70 19.04 517 25724 795583 89806623
Cytopenia 121.78 19.04 71 26170 17378 90584828
Haematotoxicity 120.50 19.04 63 26178 12472 90589734
Thrombocytopenia 114.94 19.04 212 26029 208513 90393693
Infusion related reaction 103.31 19.04 4 26237 416776 90185430
Chronic myeloid leukaemia recurrent 99.71 19.04 22 26219 280 90601926
Enterocolitis haemorrhagic 97.37 19.04 31 26210 1701 90600505
Myalgia 96.54 19.04 178 26063 174947 90427259
Pulmonary arterial hypertension 88.82 19.04 68 26173 26119 90576087
Systemic lupus erythematosus 87.92 19.04 4 26237 361892 90240314
Chronic myeloid leukaemia transformation 85.58 19.04 17 26224 124 90602082
Pancytopenia 84.31 19.04 136 26105 120127 90482079
Acne 81.62 19.04 67 26174 28440 90573766
Blast cell crisis 81.04 19.04 15 26226 71 90602135
Glossodynia 80.02 19.04 3 26238 321776 90280430
Chronic myeloid leukaemia 73.36 19.04 28 26213 2636 90599570
Pulmonary hypertension 72.90 19.04 75 26166 42448 90559758
Arthropathy 72.61 19.04 10 26231 366232 90235974
Anaemia 71.87 19.04 245 25996 352557 90249649
Leukaemia recurrent 69.24 19.04 23 26218 1444 90600762
Platelet count decreased 67.76 19.04 133 26108 136836 90465370
Joint swelling 62.48 19.04 34 26207 503266 90098940
Product dose omission issue 62.42 19.04 206 26035 291481 90310725
Therapeutic product effect decreased 61.59 19.04 5 26236 277566 90324640
Neutropenia 59.42 19.04 171 26070 224733 90377473
Large granular lymphocytosis 57.43 19.04 14 26227 282 90601924
Exposure during pregnancy 56.71 19.04 3 26238 238407 90363799
Condition aggravated 56.01 19.04 54 26187 595491 90006715
Enterococcal bacteraemia 54.71 19.04 21 26220 2007 90600199
Psoriatic arthropathy 53.91 19.04 3 26238 228332 90373874
Acute graft versus host disease 51.18 19.04 27 26214 5441 90596765
Fall 50.99 19.04 39 26202 481771 90120435
Bone marrow transplant 50.86 19.04 16 26225 844 90601362
Pericarditis 49.85 19.04 9 26232 270142 90332064
Helicobacter infection 47.88 19.04 5 26236 226845 90375361
Cytomegalovirus colitis 47.43 19.04 22 26219 3364 90598842
Impaired healing 47.33 19.04 6 26235 234193 90368013
Discomfort 46.78 19.04 11 26230 274324 90327882
Injury 45.36 19.04 3 26238 197346 90404860
Gene mutation identification test positive 44.31 19.04 10 26231 142 90602064
Type 2 diabetes mellitus 44.15 19.04 4 26237 203240 90398966
Polymerase chain reaction positive 43.13 19.04 10 26231 161 90602045
Therapeutic response delayed 42.82 19.04 14 26227 836 90601370
Splenomegaly 42.60 19.04 33 26208 12891 90589315
Lymphoid tissue hyperplasia 40.86 19.04 10 26231 205 90602001
Lipase increased 40.21 19.04 30 26211 11081 90591125
Fibromyalgia 39.99 19.04 6 26235 206263 90395943
Musculoskeletal stiffness 39.83 19.04 18 26223 296514 90305692
Drug intolerance 39.60 19.04 243 25998 447348 90154858
Folliculitis 39.49 19.04 6 26235 204347 90397859
Dyspnoea 39.17 19.04 408 25833 880547 89721659
Irritable bowel syndrome 38.07 19.04 7 26234 207441 90394765
Aspiration pleural cavity 37.87 19.04 13 26228 903 90601303
Osteoarthritis 37.25 19.04 6 26235 195724 90406482
Hepatic enzyme increased 37.13 19.04 30 26211 360706 90241500
Gene mutation 36.72 19.04 16 26225 2114 90600092
Skin disorder 36.54 19.04 49 26192 36657 90565549
Full blood count decreased 36.47 19.04 44 26197 29645 90572561
Graft versus host disease 36.39 19.04 25 26216 8119 90594087
Nephrotic syndrome 36.32 19.04 24 26217 7315 90594891
Drug hypersensitivity 35.99 19.04 49 26192 463560 90138646
Graft versus host disease in eye 35.29 19.04 8 26233 116 90602090
Central nervous system leukaemia 34.45 19.04 9 26232 242 90601964
Blood cholesterol increased 34.17 19.04 9 26232 208003 90394203
Strongyloidiasis 34.17 19.04 14 26227 1588 90600618
Pleurisy 33.61 19.04 25 26216 9192 90593014
C-reactive protein increased 33.55 19.04 6 26235 181383 90420823
Generalised oedema 33.36 19.04 34 26207 19019 90583187
Wheezing 32.68 19.04 14 26227 238066 90364140
Ill-defined disorder 32.34 19.04 7 26234 184884 90417322
Acute lymphocytic leukaemia 32.28 19.04 16 26225 2832 90599374
Constipation 31.93 19.04 163 26078 280232 90321974
Primary effusion lymphoma 31.36 19.04 5 26236 7 90602199
Sinusitis 31.18 19.04 32 26209 343056 90259150
Therapy cessation 30.92 19.04 45 26196 36316 90565890
Stem cell transplant 30.18 19.04 14 26227 2140 90600066
Philadelphia positive chronic myeloid leukaemia 30.18 19.04 6 26235 44 90602162
Confusional state 28.79 19.04 42 26199 386163 90216043
Skin toxicity 28.40 19.04 20 26221 6759 90595447
Liver injury 26.86 19.04 8 26233 170559 90431647
Chronic graft versus host disease 26.67 19.04 16 26225 4123 90598083
Gastrointestinal toxicity 26.57 19.04 22 26219 9445 90592761
Alopecia 26.19 19.04 238 26003 494833 90107373
Periorbital oedema 26.05 19.04 19 26222 6780 90595426
Hepatitis chronic active 26.03 19.04 6 26235 94 90602112
Colitis 25.45 19.04 60 26181 69882 90532324
Blister 25.25 19.04 22 26219 254976 90347230
Asthma 25.08 19.04 20 26221 242140 90360066
Febrile neutropenia 24.67 19.04 101 26140 158248 90443958
Subdural haematoma 24.35 19.04 27 26214 16618 90585588
Gastrointestinal haemorrhage 24.16 19.04 69 26172 90179 90512027
Capillary leak syndrome 24.03 19.04 13 26228 2754 90599452
Tessellated fundus 23.95 19.04 5 26236 48 90602158
Sleep disorder 23.64 19.04 14 26227 198016 90404190
Neuropathy peripheral 23.46 19.04 90 26151 136880 90465326
Acquired gene mutation 23.33 19.04 10 26231 1269 90600937
General physical health deterioration 22.40 19.04 43 26198 355072 90247134
Hypersensitivity 22.31 19.04 63 26178 454614 90147592
Cardiac failure congestive 22.23 19.04 71 26170 98623 90503583
Cardiac disorder 22.02 19.04 50 26191 56822 90545384
Blood disorder 21.65 19.04 18 26223 7772 90594434
Systemic candida 21.63 19.04 15 26226 4944 90597262
Leukocytosis 21.63 19.04 35 26206 30955 90571251
Therapy interrupted 21.61 19.04 46 26195 50062 90552144
Vomiting 20.48 19.04 331 25910 787962 89814244
Cardiac failure 20.46 19.04 74 26167 109422 90492784
Lymphocytosis 20.39 19.04 12 26229 2985 90599221
White blood cell count decreased 20.31 19.04 99 26142 167010 90435196
Bone marrow disorder 20.26 19.04 12 26229 3020 90599186
Intermittent claudication 19.95 19.04 10 26231 1813 90600393
Cytomegalovirus enterocolitis 19.88 19.04 8 26233 866 90601340
Gait inability 19.48 19.04 9 26232 146447 90455759
Blast cell proliferation 19.36 19.04 3 26238 3 90602203
Demyelinating polyneuropathy 19.30 19.04 8 26233 934 90601272
Cerebrovascular stenosis 19.29 19.04 4 26237 37 90602169
Leukaemia 19.24 19.04 14 26227 4978 90597228
Hypergammaglobulinaemia benign monoclonal 19.11 19.04 8 26233 958 90601248

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 2140.76 16.36 1072 24189 96094 42499980
Adverse event 550.07 16.36 272 24989 23368 42572706
Drug resistance 484.35 16.36 283 24978 33965 42562109
Philadelphia chromosome positive 463.46 16.36 101 25160 540 42595534
Hospitalisation 396.49 16.36 338 24923 73992 42522082
Drug intolerance 298.95 16.36 299 24962 80125 42515949
Chylothorax 295.66 16.36 79 25182 1095 42594979
Prescribed underdose 252.97 16.36 123 25138 10159 42585915
Cytogenetic analysis abnormal 242.65 16.36 62 25199 713 42595361
Pulmonary oedema 239.37 16.36 220 25041 53052 42543022
Malignant neoplasm progression 238.60 16.36 307 24954 108093 42487981
Blast crisis in myelogenous leukaemia 231.88 16.36 58 25203 608 42595466
Headache 223.81 16.36 459 24802 238910 42357164
Fatigue 221.82 16.36 661 24600 434980 42161094
Acute lymphocytic leukaemia recurrent 181.84 16.36 72 25189 3619 42592455
Fluid retention 174.85 16.36 147 25114 31472 42564602
Pericardial effusion 169.97 16.36 140 25121 29135 42566939
Pulmonary hypertension 143.72 16.36 116 25145 23453 42572621
Pulmonary arterial hypertension 102.78 16.36 68 25193 10119 42585955
Death 102.13 16.36 548 24713 470637 42125437
Acne 89.24 16.36 70 25191 13574 42582500
Rash 88.43 16.36 361 24900 276593 42319481
Chronic myeloid leukaemia recurrent 82.37 16.36 21 25240 239 42595835
Gene mutation 81.68 16.36 33 25228 1748 42594326
Large granular lymphocytosis 77.25 16.36 20 25241 243 42595831
Chronic myeloid leukaemia transformation 76.76 16.36 19 25242 190 42595884
Diarrhoea 75.26 16.36 498 24763 460351 42135723
Bone pain 71.32 16.36 79 25182 23713 42572361
Gene mutation identification test positive 70.20 16.36 18 25243 210 42595864
Hypotension 69.43 16.36 33 25228 257598 42338476
Emergency care examination 68.70 16.36 13 25248 28 42596046
Thrombocytopenia 65.40 16.36 254 25007 190025 42406049
Chronic myeloid leukaemia 64.86 16.36 31 25230 2461 42593613
Enterocolitis haemorrhagic 63.40 16.36 24 25237 1067 42595007
Philadelphia positive chronic myeloid leukaemia 61.72 16.36 15 25246 138 42595936
Loss of therapeutic response 59.47 16.36 24 25237 1267 42594807
Lymphoid tissue hyperplasia 58.36 16.36 13 25248 78 42595996
Acquired gene mutation 58.06 16.36 25 25236 1555 42594519
Oedema 57.11 16.36 107 25154 51894 42544180
Central nervous system neoplasm 56.88 16.36 13 25248 89 42595985
Leukaemia recurrent 50.85 16.36 24 25237 1852 42594222
Blast cell proliferation 46.98 16.36 8 25253 6 42596068
Treatment failure 46.73 16.36 110 25151 62514 42533560
Minimal residual disease 44.73 16.36 16 25245 605 42595469
Condition aggravated 43.97 16.36 54 25207 260700 42335374
Aspiration pleural cavity 42.41 16.36 17 25244 882 42595192
Myalgia 39.47 16.36 136 25125 95944 42500130
Cytopenia 39.06 16.36 50 25211 17447 42578627
Cytomegalovirus colitis 38.76 16.36 26 25235 3955 42592119
Nausea 38.42 16.36 381 24880 396418 42199656
Bone marrow transplant 37.55 16.36 17 25244 1192 42594882
Drug ineffective 37.37 16.36 551 24710 629646 41966428
Bradycardia 36.55 16.36 4 25257 85480 42510594
Fall 35.04 16.36 53 25208 234467 42361607
Acute kidney injury 34.95 16.36 107 25154 367230 42228844
Blast cell crisis 34.49 16.36 9 25252 113 42595961
Loss of CAR T-cell persistence 33.77 16.36 7 25254 28 42596046
Therapy cessation 33.01 16.36 50 25211 20400 42575674
Skin disorder 32.56 16.36 45 25216 16899 42579175
Pleurisy 32.15 16.36 26 25235 5264 42590810
Toxicity to various agents 30.32 16.36 56 25205 229080 42366994
Natural killer cell count increased 29.81 16.36 5 25256 3 42596071
Platelet count decreased 29.62 16.36 161 25100 138420 42457654
Bone marrow disorder 29.58 16.36 17 25244 1969 42594105
Gastrointestinal toxicity 29.49 16.36 22 25239 3957 42592117
Product dose omission issue 28.83 16.36 173 25088 154192 42441882
Myopathy toxic 28.14 16.36 12 25249 729 42595345
Intentional product use issue 28.03 16.36 100 25161 71733 42524341
Remission not achieved 27.43 16.36 8 25253 155 42595919
Therapy change 26.75 16.36 21 25240 4074 42592000
Primary effusion lymphoma 26.39 16.36 6 25255 40 42596034
Bone marrow oedema 26.19 16.36 12 25249 865 42595209
Chronic myeloid leukaemia (in remission) 25.73 16.36 4 25257 0 42596074
Infusion related reaction 25.60 16.36 3 25258 60803 42535271
Gelatinous transformation of the bone marrow 25.49 16.36 5 25256 14 42596060
Haematotoxicity 25.48 16.36 32 25229 10953 42585121
Hyperkalaemia 25.44 16.36 8 25253 80450 42515624
Anterior interosseous syndrome 25.24 16.36 5 25256 15 42596059
Overdose 24.66 16.36 16 25245 105248 42490826
Therapeutic response decreased 24.39 16.36 62 25199 36950 42559124
Clonal evolution 24.38 16.36 7 25254 128 42595946
Hepatotoxicity 24.22 16.36 49 25212 25118 42570956
Right ventricular dysfunction 23.53 16.36 13 25248 1396 42594678
Bone marrow failure 23.45 16.36 57 25204 33036 42563038
Drug clearance decreased 23.09 16.36 15 25246 2163 42593911
Confusional state 23.02 16.36 40 25221 167557 42428517
Subdural hygroma 22.90 16.36 9 25252 443 42595631
Dyspnoea 22.68 16.36 378 24883 442243 42153831
Leukaemic infiltration extramedullary 22.36 16.36 7 25254 174 42595900
Neoplasm recurrence 22.32 16.36 16 25245 2708 42593366
Myeloid leukaemia 22.23 16.36 9 25252 479 42595595
Hyperplasia 22.09 16.36 10 25251 701 42595373
Asthma 21.95 16.36 5 25256 62309 42533765
Inappropriate schedule of product administration 21.89 16.36 15 25246 95887 42500187
Exercise tolerance decreased 21.45 16.36 22 25239 6044 42590030
Chromosome analysis abnormal 21.40 16.36 7 25254 201 42595873
Oxygen saturation decreased 21.23 16.36 6 25255 64681 42531393
Tremor 21.03 16.36 16 25245 96913 42499161
Second primary malignancy 20.80 16.36 27 25234 9548 42586526
Eyelid oedema 20.77 16.36 21 25240 5674 42590400
Central nervous system leukaemia 20.53 16.36 8 25253 385 42595689
Cardiac arrest 20.17 16.36 21 25240 109299 42486775
Leukocytosis 19.81 16.36 50 25211 29658 42566416
Syncope 19.61 16.36 18 25243 99388 42496686
Drug hypersensitivity 19.60 16.36 18 25243 99371 42496703
Acute lymphocytic leukaemia refractory 19.56 16.36 6 25255 139 42595935
Hallucination 19.50 16.36 5 25256 57502 42538572
Polymerase chain reaction positive 19.40 16.36 6 25255 143 42595931
Subclavian artery stenosis 19.00 16.36 5 25256 65 42596009
Hyphaema 18.87 16.36 9 25252 711 42595363
Bone neoplasm 18.87 16.36 7 25254 294 42595780
Graft versus host disease 18.62 16.36 30 25231 12895 42583179
Rectosigmoid cancer 17.91 16.36 6 25255 186 42595888
B-cell small lymphocytic lymphoma 17.81 16.36 6 25255 189 42595885
Allogenic bone marrow transplantation therapy 17.55 16.36 4 25257 27 42596047
Cerebellar syndrome 17.28 16.36 14 25247 2841 42593233
Lactic acidosis 17.27 16.36 3 25258 45258 42550816
Mutagenic effect 17.22 16.36 3 25258 3 42596071
Pancytopenia 17.13 16.36 124 25137 117619 42478455
Hyponatraemia 17.07 16.36 21 25240 101441 42494633
Peripheral artery stenosis 16.90 16.36 9 25252 898 42595176
Loss of consciousness 16.75 16.36 18 25243 92336 42503738
Cardio-respiratory arrest 16.55 16.36 7 25254 58629 42537445
Intentional overdose 16.47 16.36 5 25256 51451 42544623

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 3383.76 15.84 1533 39473 176176 110372117
Philadelphia chromosome positive 669.92 15.84 134 40872 766 110547527
Chylothorax 659.53 15.84 138 40868 1018 110547275
Drug resistance 652.89 15.84 348 40658 56026 110492267
Hospitalisation 540.91 15.84 437 40569 142056 110406237
Pulmonary oedema 528.95 15.84 375 40631 100284 110448009
Blast crisis in myelogenous leukaemia 382.17 15.84 86 40920 922 110547371
Pericardial effusion 381.14 15.84 247 40759 56970 110491323
Malignant neoplasm progression 363.88 15.84 383 40623 174184 110374109
Adverse event 359.27 15.84 308 40698 108501 110439792
Acute lymphocytic leukaemia recurrent 349.15 15.84 116 40890 5671 110542622
Cytogenetic analysis abnormal 346.89 15.84 83 40923 1186 110547107
Fatigue 326.34 15.84 1088 39918 1214870 109333423
Death 281.66 15.84 724 40282 698145 109850148
Fluid retention 263.58 15.84 243 40763 94064 110454229
Headache 250.68 15.84 806 40200 881571 109666722
Emergency care examination 209.54 15.84 41 40965 205 110548088
Diarrhoea 194.49 15.84 885 40121 1138620 109409673
Pulmonary arterial hypertension 184.06 15.84 127 40879 32441 110515852
Bone pain 182.26 15.84 168 40838 64965 110483328
Rash 176.76 15.84 685 40321 820279 109728014
Thrombocytopenia 166.15 15.84 386 40620 348499 110199794
Prescribed underdose 164.94 15.84 159 40847 65015 110483278
Pulmonary hypertension 163.44 15.84 147 40859 55073 110493220
Chronic myeloid leukaemia transformation 152.55 15.84 33 40973 290 110548003
Enterocolitis haemorrhagic 152.31 15.84 51 40955 2553 110545740
Acne 151.20 15.84 114 40892 33406 110514887
Large granular lymphocytosis 141.81 15.84 34 40972 490 110547803
Nausea 132.23 15.84 845 40161 1234845 109313448
Infusion related reaction 116.60 15.84 6 41000 381156 110167137
Gene mutation 113.23 15.84 44 40962 3385 110544908
Chronic myeloid leukaemia 107.20 15.84 45 40961 4228 110544065
Chronic myeloid leukaemia recurrent 103.53 15.84 25 40981 372 110547921
Rheumatoid arthritis 97.40 15.84 3 41003 299610 110248683
Cytomegalovirus colitis 94.26 15.84 48 40958 7013 110541280
Philadelphia positive chronic myeloid leukaemia 92.03 15.84 20 40986 180 110548113
Cytopenia 90.73 15.84 81 40925 30035 110518258
Platelet count decreased 90.51 15.84 237 40769 230206 110318087
Haematotoxicity 89.13 15.84 69 40937 21013 110527280
Myalgia 84.57 15.84 226 40780 222155 110326138
Systemic lupus erythematosus 81.07 15.84 3 41003 254335 110293958
Condition aggravated 80.98 15.84 92 40914 734744 109813549
Fall 77.49 15.84 66 40940 603416 109944877
Acquired gene mutation 75.84 15.84 31 40975 2723 110545570
Drug intolerance 75.81 15.84 325 40681 406187 110142106
Arthropathy 75.48 15.84 9 40997 287513 110260780
Wound 73.92 15.84 3 41003 234434 110313859
Lower respiratory tract infection 73.77 15.84 4 41002 243102 110305191
Blast cell crisis 72.37 15.84 16 40990 157 110548136
Leukaemia recurrent 72.00 15.84 31 40975 3100 110545193
Pancytopenia 71.74 15.84 205 40801 209408 110338885
Gene mutation identification test positive 68.06 15.84 17 40989 293 110548000
Glossodynia 66.30 15.84 4 41002 222000 110326293
Therapy cessation 65.50 15.84 82 40924 44775 110503518
Therapeutic product effect decreased 63.26 15.84 8 40998 244308 110303985
Pleurisy 63.20 15.84 45 40961 12071 110536222
Psoriatic arthropathy 60.44 15.84 3 41003 196758 110351535
Aspiration pleural cavity 59.89 15.84 23 40983 1714 110546579
Hypotension 58.29 15.84 65 40941 523784 110024509
Bone marrow transplant 57.30 15.84 22 40984 1638 110546655
Full blood count decreased 57.29 15.84 65 40941 32034 110516259
Central nervous system leukaemia 57.19 15.84 17 40989 574 110547719
Mobility decreased 56.36 15.84 10 40996 237412 110310881
Musculoskeletal stiffness 56.10 15.84 17 40989 279805 110268488
Primary effusion lymphoma 55.89 15.84 11 40995 57 110548236
Joint swelling 54.91 15.84 50 40956 442795 110105498
Skin disorder 54.16 15.84 73 40933 42840 110505453
Lymphoid tissue hyperplasia 53.90 15.84 14 40992 284 110548009
Gastrointestinal toxicity 52.68 15.84 39 40967 11109 110537184
Osteoarthritis 52.45 15.84 4 41002 182619 110365674
Drug hypersensitivity 52.00 15.84 55 40951 454035 110094258
Anaemia 50.82 15.84 362 40644 546724 110001569
Blast cell proliferation 50.73 15.84 8 40998 6 110548287
Exposure during pregnancy 50.03 15.84 3 41003 167421 110380872
Oedema 49.68 15.84 181 40825 209795 110338498
Loss of therapeutic response 48.52 15.84 22 40984 2488 110545805
Fibromyalgia 48.36 15.84 4 41002 170905 110377388
Wheezing 46.84 15.84 18 40988 255212 110293081
Product dose omission issue 45.83 15.84 238 40768 321544 110226749
Type 2 diabetes mellitus 45.40 15.84 6 41000 177226 110371067
Impaired healing 45.16 15.84 9 40997 196708 110351585
Therapy change 45.07 15.84 34 40972 9963 110538330
Febrile neutropenia 44.91 15.84 234 40772 316533 110231760
Splenomegaly 44.38 15.84 50 40956 24448 110523845
Bone marrow failure 44.19 15.84 78 40928 57770 110490523
C-reactive protein increased 44.11 15.84 13 40993 217906 110330387
Injury 43.09 15.84 7 40999 177258 110371035
Helicobacter infection 42.43 15.84 8 40998 181869 110366424
Polymerase chain reaction positive 42.19 15.84 12 40994 346 110547947
Asthma 42.18 15.84 20 40986 250271 110298022
Clonal evolution 41.55 15.84 11 40995 241 110548052
Natural killer cell count increased 41.32 15.84 7 40999 12 110548281
Confusional state 41.18 15.84 69 40937 468611 110079682
Graft versus host disease 40.40 15.84 42 40964 18764 110529529
Discomfort 39.63 15.84 15 40991 214692 110333601
Enterococcal bacteraemia 39.20 15.84 23 40983 4438 110543855
Lipase increased 38.86 15.84 41 40965 18631 110529662
Mucosal inflammation 38.85 15.84 100 40906 96041 110452252
Generalised oedema 38.39 15.84 52 40954 30652 110517641
Neutropenia 38.37 15.84 254 40752 374366 110173927
Drug clearance decreased 38.20 15.84 22 40984 4100 110544193
Therapy interrupted 37.82 15.84 67 40939 49755 110498538
Folliculitis 37.80 15.84 8 40998 167645 110380648
Dyspnoea 37.57 15.84 597 40409 1106275 109442018
Leukocytosis 36.58 15.84 69 40937 53759 110494534
Chromosome analysis abnormal 35.61 15.84 10 40996 275 110548018
Chronic myeloid leukaemia (in remission) 35.52 15.84 6 41000 10 110548283
Nephrotic syndrome 35.45 15.84 34 40972 13797 110534496
Bone marrow disorder 35.09 15.84 21 40985 4202 110544091
Colitis 34.90 15.84 100 40906 102223 110446070
Irritable bowel syndrome 34.72 15.84 9 40997 164206 110384087
Drug ineffective 34.01 15.84 769 40237 1519771 109028522
Sleep disorder 33.27 15.84 16 40990 198628 110349665
Overdose 33.22 15.84 23 40983 233771 110314522
Peripheral artery stenosis 33.10 15.84 14 40992 1340 110546953
Psoriasis 32.99 15.84 6 41000 139987 110408306
Therapeutic response delayed 32.74 15.84 14 40992 1376 110546917
Intentional overdose 32.73 15.84 5 41001 132496 110415797
Oxygen saturation decreased 32.44 15.84 9 40997 156973 110391320
Blood cholesterol increased 32.32 15.84 14 40992 184771 110363522
Bone development abnormal 32.11 15.84 7 40999 64 110548229
Acute graft versus host disease 31.77 15.84 31 40975 12850 110535443
Loss of CAR T-cell persistence 31.75 15.84 6 41000 24 110548269
Malaise 31.57 15.84 135 40871 671684 109876609
White blood cell count increased 31.45 15.84 93 40913 96749 110451544
Acute lymphocytic leukaemia 31.43 15.84 22 40984 5743 110542550
Minimal residual disease 30.66 15.84 12 40994 941 110547352
Sinusitis 30.63 15.84 39 40967 296649 110251644
Inappropriate schedule of product administration 30.33 15.84 19 40987 203618 110344675
Skin toxicity 30.27 15.84 29 40977 11754 110536539
Periorbital oedema 29.88 15.84 27 40979 10165 110538128
Central nervous system neoplasm 29.85 15.84 8 40998 184 110548109
Product use in unapproved indication 29.12 15.84 78 40928 447299 110100994
Blister 28.96 15.84 25 40981 227351 110320942
Hepatic enzyme increased 28.39 15.84 47 40959 320845 110227448
Hypersensitivity 28.18 15.84 68 40938 403930 110144363
Acute graft versus host disease in intestine 27.26 15.84 20 40986 5619 110542674
Ill-defined disorder 27.25 15.84 12 40994 156841 110391452
Graft versus host disease in eye 26.86 15.84 9 40997 451 110547842
White blood cell count decreased 26.86 15.84 161 40845 229229 110319064
Intentional product misuse 26.76 15.84 8 40998 132896 110415397
Cardiac disorder 26.45 15.84 75 40931 76205 110472088
Obesity 26.40 15.84 5 41001 113346 110434947
Anterior interosseous syndrome 25.90 15.84 5 41001 23 110548270
Remission not achieved 25.67 15.84 9 40997 518 110547775
Pericarditis 25.66 15.84 26 40980 219088 110329205
Toxicity to various agents 25.46 15.84 92 40914 480463 110067830
Wound infection 25.35 15.84 3 41003 96462 110451831
Urticaria 25.26 15.84 50 40956 318807 110229486
Therapeutic response decreased 25.23 15.84 86 40920 96413 110451880
Strongyloidiasis 24.82 15.84 18 40988 4968 110543325
Intermittent claudication 24.67 15.84 16 40990 3685 110544608
Subdural hygroma 24.44 15.84 9 40997 597 110547696
Leukaemia 24.20 15.84 21 40985 7497 110540796
Lactic acidosis 24.11 15.84 3 41003 92808 110455485
Metabolic acidosis 24.10 15.84 4 41002 99740 110448553
Liver injury 23.86 15.84 13 40993 150400 110397893
Medication error 23.80 15.84 5 41001 105361 110442932
Syncope 23.75 15.84 24 40982 202512 110345781
Hypercholesterolaemia 23.44 15.84 3 41003 90834 110457459
Haemothorax 23.36 15.84 20 40986 7011 110541282
Somnolence 23.25 15.84 47 40959 297402 110250891
Eye swelling 23.25 15.84 43 40963 33005 110515288
Dry mouth 23.10 15.84 24 40982 199924 110348369
Systemic candida 22.74 15.84 23 40983 9951 110538342
Tessellated fundus 22.72 15.84 5 41001 48 110548245
Hepatotoxicity 22.63 15.84 63 40943 63337 110484956
Eyelid oedema 22.44 15.84 28 40978 15234 110533059
Hyperplasia 22.26 15.84 11 40995 1507 110546786
Osteoporosis 22.20 15.84 3 41003 87149 110461144
Stem cell transplant 22.08 15.84 16 40990 4411 110543882
Growth retardation 21.87 15.84 13 40993 2569 110545724
Arthritis 21.86 15.84 18 40988 167568 110380725
Lymphocytosis 21.34 15.84 17 40989 5394 110542899
Bone marrow oedema 21.31 15.84 12 40994 2144 110546149
Right ventricular dysfunction 21.26 15.84 14 40992 3309 110544984
Peripheral venous disease 21.18 15.84 3 41003 84114 110464179
Product administered to patient of inappropriate age 21.06 15.84 20 40986 8016 110540277
Transplant 21.00 15.84 10 40996 1264 110547029
Delirium 20.94 15.84 12 40994 135013 110413280
Myeloid leukaemia 20.94 15.84 9 40997 896 110547397
Blood pressure systolic increased 20.80 15.84 3 41003 82988 110465305
Cytomegalovirus enterocolitis 20.68 15.84 12 40994 2269 110546024
Myopathy toxic 20.63 15.84 10 40996 1315 110546978
Drug reaction with eosinophilia and systemic symptoms 20.50 15.84 3 41003 82092 110466201
Tremor 20.44 15.84 27 40979 202205 110346088
Peripheral arterial occlusive disease 20.43 15.84 21 40985 9259 110539034
Subdural haematoma 20.29 15.84 43 40963 36411 110511882
Second primary malignancy 20.20 15.84 29 40977 18039 110530254
Cytomegalovirus infection reactivation 19.87 15.84 29 40977 18304 110529989
Cardiac failure 19.65 15.84 128 40878 187498 110360795
Drug-induced liver injury 19.60 15.84 10 40996 120057 110428236
Gelatinous transformation of the bone marrow 19.55 15.84 4 41002 26 110548267
Blood disorder 19.46 15.84 21 40985 9789 110538504
Gait disturbance 19.25 15.84 47 40959 278161 110270132
Face oedema 19.23 15.84 40 40966 33429 110514864
Hyphaema 19.20 15.84 9 40997 1098 110547195
General physical health deterioration 19.01 15.84 87 40919 425208 110123085
Acute myeloid leukaemia 18.99 15.84 43 40963 38067 110510226
Graft versus host disease in skin 18.76 15.84 19 40987 8235 110540058
Constipation 18.73 15.84 209 40797 357577 110190716
Blast cell count increased 18.63 15.84 10 40996 1627 110546666
Hydrothorax 18.51 15.84 10 40996 1648 110546645
Blood pressure increased 18.39 15.84 43 40963 258330 110289963
Inflammation 18.33 15.84 27 40979 193211 110355082
Hepatitis chronic active 18.10 15.84 6 41000 291 110548002
Blood pressure fluctuation 18.08 15.84 3 41003 74821 110473472
Sciatica 17.82 15.84 6 41000 92393 110455900
Neoplasm malignant 17.51 15.84 41 40965 37102 110511191
Multiple-drug resistance 17.44 15.84 23 40983 13212 110535081
Allogenic bone marrow transplantation therapy 17.44 15.84 4 41002 47 110548246
Mutagenic effect 17.41 15.84 3 41003 6 110548287
Depressed level of consciousness 17.38 15.84 10 40996 112268 110436025
Gait inability 17.35 15.84 15 40991 136361 110411932
Loss of consciousness 17.13 15.84 29 40977 196277 110352016
Cerebellar syndrome 17.12 15.84 16 40990 6286 110542007
Leukaemic infiltration extramedullary 17.10 15.84 6 41000 346 110547947
Cardiac tamponade 17.03 15.84 21 40985 11286 110537007
Hyperhidrosis 16.96 15.84 27 40979 187271 110361022
Pneumonia fungal 16.96 15.84 24 40982 14730 110533563
Product quality issue 16.79 15.84 4 41002 77295 110470998
Severe invasive streptococcal infection 16.79 15.84 4 41002 56 110548237
Right ventricular enlargement 16.79 15.84 8 40998 1013 110547280
Tumour lysis syndrome 16.76 15.84 36 40970 30765 110517528
Cytomegalovirus infection 16.46 15.84 51 40955 54393 110493900
Sedation 16.39 15.84 3 41003 69680 110478613
Hypergammaglobulinaemia benign monoclonal 16.30 15.84 8 40998 1081 110547212
Pyrexia 16.28 15.84 442 40564 897823 109650470
Therapy non-responder 16.28 15.84 107 40899 157200 110391093
Fusarium infection 16.11 15.84 11 40995 2760 110545533
Ventricular enlargement 16.10 15.84 7 40999 717 110547576
Hyperkalaemia 16.02 15.84 16 40990 135780 110412513
Road traffic accident 16.02 15.84 10 40996 107388 110440905
Bacteraemia 16.00 15.84 43 40963 42347 110505946
Exercise tolerance decreased 15.95 15.84 21 40985 12046 110536247
Bone marrow necrosis 15.91 15.84 6 41000 425 110547868

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
MeSH PA D000092004 Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug

Related Drugs by ATC class:

L01EA BCR-ABL tyrosine kinase inhibitors 5 drugs
asciminibbosutinibimatinibnilotinibponatinib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Blastic phase chronic myeloid leukemia indication 413656006
Chronic phase chronic myeloid leukemia indication 413847001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Torsades de pointes contraindication 31722008
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Pleural Effusions contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.56 acidic
pKa2 7.72 Basic
pKa3 4.89 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11202778 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 11324745 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12433891 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL 12544376 Jan. 22, 2041 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
100MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL Dec. 5, 2026 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM A DRUG INTERACTION STUDY WITH GASTRIC ACID REDUCING AGENTS
140MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL Dec. 5, 2026 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM A DRUG INTERACTION STUDY WITH GASTRIC ACID REDUCING AGENTS
20MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL Dec. 5, 2026 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM A DRUG INTERACTION STUDY WITH GASTRIC ACID REDUCING AGENTS
50MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL Dec. 5, 2026 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM A DRUG INTERACTION STUDY WITH GASTRIC ACID REDUCING AGENTS
70MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL Dec. 5, 2026 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM A DRUG INTERACTION STUDY WITH GASTRIC ACID REDUCING AGENTS
80MG PHYRAGO HANDA THERAP N216099 Dec. 5, 2023 RX TABLET ORAL Dec. 5, 2026 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM A DRUG INTERACTION STUDY WITH GASTRIC ACID REDUCING AGENTS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tyrosine-protein kinase ABL1 Kinase INHIBITOR IC50 9.60 IUPHAR CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.24 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Tyrosine-protein kinase Lck Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Tyrosine-protein kinase Yes Kinase INHIBITOR Kd 9.52 CHEMBL CHEMBL
Tyrosine-protein kinase Fyn Kinase INHIBITOR Kd 9.10 CHEMBL CHEMBL
Ephrin type-A receptor 2 Kinase INHIBITOR Kd 9.07 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 9.20 CHEMBL CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.30 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.49 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.41 CHEMBL
Vascular endothelial growth factor receptor 1 Kinase Kd 5.30 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase Kd 5.54 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 9.24 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 9.33 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase Kd 5.85 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.14 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.41 CHEMBL
Tyrosine-protein kinase HCK Kinase INHIBITOR Kd 9.46 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 7.26 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.52 CHEMBL
cAMP-dependent protein kinase catalytic subunit beta Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.54 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.46 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 9 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 9.62 CHEMBL
Tyrosine-protein kinase Lyn Kinase INHIBITOR Kd 9.24 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 8.85 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 5.19 CHEMBL
LIM domain kinase 1 Kinase Kd 6.24 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 5.92 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 9.77 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.39 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 9.62 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 8.92 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.45 CHEMBL
Protein kinase C theta type Kinase Kd 6.15 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 5.68 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.70 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 5.82 CHEMBL
Tyrosine-protein kinase Fgr Kinase INHIBITOR Kd 9.30 CHEMBL
Aurora kinase A Kinase Kd 5.03 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.68 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 10.03 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 7.57 CHEMBL
Tyrosine-protein kinase FRK Kinase INHIBITOR Kd 9.51 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.35 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 6.51 CHEMBL
Cyclin-G-associated kinase Kinase Kd 8.59 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.51 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 9.35 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 5.42 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 8.25 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6.14 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.16 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 9.47 CHEMBL
Activin receptor type-1B Kinase Kd 6.48 CHEMBL
Serine/threonine-protein kinase receptor R3 Kinase Kd 6.34 CHEMBL
Activin receptor type-1 Kinase Kd 6.21 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.54 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase IC50 6.64 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 8.11 CHEMBL
MAP kinase-activated protein kinase 2 Kinase Kd 6.27 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 8.85 CHEMBL
Tyrosine-protein kinase Tec Kinase Kd 7.89 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 9.41 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.17 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.96 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.42 CHEMBL
Wee1-like protein kinase Kinase Kd 5.15 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 5.47 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.35 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 8.68 CHEMBL
LIM domain kinase 2 Kinase Kd 7.07 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.59 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 8.19 CHEMBL
Activin receptor type-2A Kinase Kd 6.68 CHEMBL
Activin receptor type-2B Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 7.96 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.52 CHEMBL
Myotonin-protein kinase Kinase Kd 5.89 CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase MRCK gamma Kinase Kd 5.92 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.01 CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.19 CHEMBL
Aurora kinase B Kinase IC50 5.19 CHEMBL
Tyrosine-protein kinase Blk Kinase INHIBITOR Kd 9.68 CHEMBL
Bone morphogenetic protein receptor type-1A Kinase Kd 5.15 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.51 CHEMBL
Serine/threonine-protein kinase MRCK alpha Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 6.13 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 8.41 CHEMBL
Tyrosine-protein kinase Srms Kinase INHIBITOR Kd 7.89 CHEMBL
Dual specificity testis-specific protein kinase 1 Kinase Kd 7.48 CHEMBL
TGF-beta receptor type-1 Kinase Kd 6.64 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 8.39 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 8.16 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.89 CHEMBL
Misshapen-like kinase 1 Kinase Kd 6.37 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 10.41 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 5.28 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.55 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.34 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.11 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 7.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.90 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 7.55 CHEMBL
Wee1-like protein kinase 2 Kinase Kd 6.70 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 7.28 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 5.49 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.27 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.48 CHEMBL
Serine/threonine-protein kinase Nek11 Kinase Kd 6.33 CHEMBL
MAP kinase p38 Kinase IC50 7 CHEMBL
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 Kinase IC50 5.77 CHEMBL
Bcr/Abl fusion protein Kinase IC50 9.10 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 6.24 CHEMBL
Myelin transcription factor 1 Transcription factor IC50 7.20 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 6.19 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.84 CHEMBL
Transthyretin Secreted Kd 5.51 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.70 CHEMBL
Epidermal growth factor receptor Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase mTOR Kinase IC50 4.46 CHEMBL
Breakpoint cluster region protein Kinase Kd 8.30 CHEMBL
Proto-oncogene tyrosine-protein kinase LCK Kinase Ki 10.19 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 7.96 CHEMBL
Tubulin alpha-1A chain Structural Kd 7.26 CHEMBL
Tyrosine-protein kinase Blk Kinase IC50 8.10 CHEMBL
Quinolone resistance protein NorA Transporter IC50 4.94 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.19 CHEMBL

External reference:

IDSource
4025488 VUID
N0000179780 NUI
D03658 KEGG_DRUG
863127-77-9 SECONDARY_CAS_RN
475342 RXNORM
C1455147 UMLSCUI
CHEBI:70839 CHEBI
1N1 PDB_CHEM_ID
CHEMBL5416410 ChEMBL_ID
CHEMBL1421 ChEMBL_ID
D000069439 MESH_DESCRIPTOR_UI
DB01254 DRUGBANK_ID
5678 IUPHAR_LIGAND_ID
RBZ1571X5H UNII
3062316 PUBCHEM_CID
21648 MMSL
293976 MMSL
83173 MMSL
d05831 MMSL
011616 NDDF
422756008 SNOMEDCT_US
423658008 SNOMEDCT_US
4025488 VANDF
RBZ1571X5H INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0524 TABLET 70 mg ORAL NDA 26 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0527 TABLET 20 mg ORAL NDA 26 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0528 TABLET 50 mg ORAL NDA 26 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0852 TABLET 100 mg ORAL NDA 26 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0855 TABLET 80 mg ORAL NDA 26 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0857 TABLET 140 mg ORAL NDA 26 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 0480-3523 TABLET, FILM COATED 80 mg ORAL ANDA 28 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 0480-3524 TABLET, FILM COATED 140 mg ORAL ANDA 28 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 0480-5101 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 0480-5102 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 0480-5103 TABLET, FILM COATED 70 mg ORAL ANDA 28 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 0480-5104 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-599 TABLET, FILM COATED 20 mg ORAL ANDA 24 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-600 TABLET, FILM COATED 50 mg ORAL ANDA 24 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-601 TABLET, FILM COATED 70 mg ORAL ANDA 24 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-602 TABLET, FILM COATED 80 mg ORAL ANDA 24 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-603 TABLET, FILM COATED 100 mg ORAL ANDA 24 sections
Dasatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-604 TABLET, FILM COATED 140 mg ORAL ANDA 24 sections
DASATINIB Human Prescription Drug Label 1 46708-684 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 46708-685 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 46708-686 TABLET, FILM COATED 70 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 46708-687 TABLET, FILM COATED 80 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 46708-688 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 46708-689 TABLET, FILM COATED 140 mg ORAL ANDA 28 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 54868-5759 TABLET 70 mg ORAL NDA 28 sections
DASATINIB Human Prescription Drug Label 1 59651-542 TABLET 20 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 59651-543 TABLET 50 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 59651-544 TABLET 70 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 59651-545 TABLET 80 mg ORAL ANDA 28 sections
DASATINIB Human Prescription Drug Label 1 59651-546 TABLET 100 mg ORAL ANDA 28 sections